Poor mobilizer: A retrospective study on proven and predicted incidence according to GITMO criteria

Transfusion and Apheresis Science

Volumn 47, Issue 2, 2012, Pages 217-221

  Piccirillo, Nicola ^a   Vacca, Michele ^b   Lanti, Alessandro ^c   Ipsevich, Francesco ^b   Maresca, Maddalena ^a   Fiorelli, Elena ^c,d   Bianchi, Maria ^a   Adorno, Gaspare ^c,d   Pierelli, Luca ^b   Majolino, Ignazio ^b   Leone, Giuseppe ^a   Zini, Gina ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UOC Ematologia e SIMT AO S Camillo Forlanini   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CLINICAL ASSESSMENT TOOL; FEASIBILITY STUDY; FEMALE; GITMO CRITERIA; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYELOMA; RETROSPECTIVE STUDY; REVIEW; STEM CELL MOBILIZATION;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84865420767     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2012.06.008     Document Type: Review

References (27)

1. Mohty M., Ho A.D. In and out of the niche: perspectives in mobilization of hematopoietic stem cells. Exp Hematol 2011, 39(7):723-729.
2. Schmitz N., Linch D.C., Dreger P., Goldstone A.H., Boogaerts M.A., Ferrant A., et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996, 347(8998):353-357.
3. Smith T.J., Hillner B.E., Schmitz N., Linch D.C., Dreger P., Goldstone A.H., et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997, 15(1):5-10.
4. + cell yield. J Clin Apher 2011, 26(3):111-115.
5. Boeve S., Strupeck J., Creech S., Stiff P.J. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant 2004, 33(10):997-1003.
6. Perseghin P., Terruzzi E., Dassi M., Baldini V., Parma M., Coluccia P., et al. Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci 2009, 41(1):33-37.
7. Pusic I., Jiang S.Y., Landua S., Uy G.L., Rettig M.P., Cashen A.F., et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008, 14(9):1045-1056.
8. Sugrue M.W., Williams K., Pollock B.H., et al. Characterization and outcome of ''hard tomobilize'' lymphomapatients undergoing autologous stemcell transplantation. Leuk Lymphoma 2000, 39:509-519.
9. Tarella C., Di Nicola M., Caracciolo D., et al. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplant 2002, 30:725-732.
10. Gordan L.N., Sugrue M.W., Lynch J.W., et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003, 44:815-820.
11. Kuittinen T., Nousiainen T., Halonen P., Mahlamaki E., Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004, 33:907-912.
12. Pavone V., Gaudio F., Console G., et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006, 37:719-724.
13. Akhtar S., Weshi A.E., Rahal M., et al. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients. Leuk Lymphoma 2008, 49:769-778.
14. Hosing C., Saliba R.M., Ahlawat S., Korbling M., Kebriaei P., Alousi A., et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009, 84(6):335-337.
15. Wuchter P., Ran D., Bruckner T., Schmitt T., Witzens-Harig M., Neben K., et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010, 16(4):490-499.
16. Ameen R.M., Alshemmari S.H., Alqallaf D. Factors associated with successful mobilization of progenitor hematopoietic stem cells among patients with lymphoid malignancies. Clin Lymphoma Myeloma 2008, 8(2):106-110.
17. Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Am Soc Hemtol Educ, Progr 2009, 2009:507-519.
18. Voss M.H., Feldman D.R., Motzer R.J. High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. Expert Rev Anticancer Ther 2011, 11(7):1091-1103.
19. Berry D.A., Ueno N.T., Johnson M.M., Lei X., Caputo J., Smith D.A., et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol 2011, 29(24):3224-3231.
20. Gidron A, Singh V, Egan K, Mehta J. Significance of low peripheral blood CD34+ cell numbers prior to leukapheresis: what should the threshold required for apheresis be? Bone Marrow Transplant 2008;42(7):439-42.
21. DiPersio J.F., Micallef I.N., Stiff P.J., Bolwell B.J., Maziarz R.T., Jacobsen E., et al. Phase III prospective randomized doubleblind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non- Hodgkin's lymphoma. J Clin Oncol 2009, 27:4767-4773.
22. DiPersio J.F., Stadtmauer E.A., Nademanee A., Micallef I.N., Stiff P.J., Kaufman J.L., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
23. Bensinger W., DiPersio J.F., McCarty J.M. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009, 43:181-195.
24. Olivieri A., Marchetti M., Lemoli R., Tarella C., Iacone A., Lanza F., et al. Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo italianoTrapianto di Midollo Osseo. Bone Marrow Transplant 2012, 47(3):342-351.
25. Herbert K.E., Levesqu e J.P., Mills A.K., Gottlieb D.J., Cooney J., Szer J., et al. How we mobilize haemopoietic stem cells. Intern Med J 2011, 41(8):588-594.
26. Greenbaum A.M., Link D.C. Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization. Leukemia 2011, 25(2):211-217.
27. To L.B., Levesque J.P., Herbert K.E. How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011, 118(17):4530-4540.